References
- Adams, V., Murphy, M. and Clarke, A. E. (2009) Anticipation: Technoscience, life, affect, temporality, Subjectivity, 28(1), pp. 246–265. doi: 10.1057/sub.2009.18
- Anderson, B. (2010) Preemption, precaution, preparedness: Anticipatory action and future geographies. Progress in Human Geography, 34(6), pp. 777–798. doi:10.1177/0309132510362600.
- Baker, J. R. (2016) A statement from the CEO of FARE. Food Allergy Research and Education. Available at http://www.foodallergy.org/press-room/fare-statements/090716#.WHa6brYrKgw (accessed 12 September 2016).
- Beck, U. (1992) Risk Society: Towards a New Modernity (Newbury Park, CA: Sage).
- Beck, U. (1999) World Risk Society (Cambridge, MA: Polity Press).
- Besky, S. (2016) The future of price: Communicative infrastructures and the financialization of Indian Tea, Cultural Anthropology, 31(1), pp. 4–29. doi: 10.14506/ca31.1.02
- Bilton, N. (2016) Exclusive: How Elizabeth Holmes’s house of cards came tumbling down, Vanity Fair, October. Available at http://www.vanityfair.com/news/2016/09/elizabeth-holmes-theranos-exclusive (accessed 24 April 2017).
- Birch, K. (2017) Rethinking value in the bio-economy: Finance, assetization, and the management of value, Science, Technology, & Human Values, 42(3), pp. 460–490. doi: 10.1177/0162243916661633
- Çalışkan, K. and Callon, M. (2009) Economization, part 1: shifting attention from the economy towards processes of economization, Economy and Society, 38(3), pp. 369–398. doi: 10.1080/03085140903020580
- Çalışkan, K. and Callon, M. (2010) Economization, part 2: a research programme for the study of markets, Economy and Society, 39(1), pp. 1–32. doi: 10.1080/03085140903424519
- Clarke, T., et al. (2016) Early release of selected estimates based on data from the January–March 2015 National Health Interview Survey. Division of Health Interview Statistics, National Center for Health Statistics. Available at: https://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201605.pdf (accessed 27 January 2017).
- Cooper, M. and Waldby, C. (2014) Clinical Labor: Tissue Donors and Research Subjects in the Global Bioeconomy (Durham: Duke University Press).
- Dennis, S. T. (2016) Mylan CEO behind EpiPen price Furor praised by senator father, Bloomberg Politics. Available at http://www.bloomberg.com/politics/articles/2016-09-07/senator-praises-generous-daughter-who-raised-prices-on-epipens (accessed 24 April 2017).
- Dumit, J. (2012) Drugs for Life: How Pharmaceutical Companies Define Our Health (Durham: Duke University Press).
- Fortun, M. (2001) Mediated speculations in the genomics futures markets, New Genetics & Society, 20(2), pp. 139–156. doi: 10.1080/14636770124557
- Glabau, D. (2016) The moral life of epinephrine in the United States, Medicine Anthropology Theory, 3(3), pp. 1–22.
- Glabau, D., Fiereck, K., and Sherman, M. (2017) Biofinance: Speculation, risk, debt, and value from bios: A conference report. Somatosphere. Available at http://somatosphere.net/2017/02/biofinance-speculation-risk-debt-and-value-from-bios-a-conference-report.html (accessed 24 April 2017).
- Ho, K. (2009) Liquidated: An Ethnography of Wall Street (Durham: Duke University Press).
- Jain, S. L. (2010) Be prepared, in: J. M. Metzl and A. Kirkland (Eds) Against Health: How Health Became the New Morality, pp. 170–182 (New York: New York University Press).
- Jain, S. L. (2013) Malignant: How Cancer Becomes Us (Berkeley: University of California Press).
- Jasanoff, S. (1990) American exceptionalism and the political acknowledgment of risk, Daedalus, 119(4), pp. 61–81.
- Jasanoff, S., and Kim, S.-H. (2009) Containing the atom: Sociotechnical imaginaries and nuclear power in the United States and South Korea, Minerva, 47(2), pp. 119–146. doi: 10.1007/s11024-009-9124-4
- Kaufman, S. (2015) Ordinary Medicine: Extraordinary Treatments, Longer Lives, and Where to Draw the Line (Durham, NC: Duke University Press).
- Kaufman, S. and Fjord, L. (2011) Medicare, ethics, and reflexive longevity: governing time and treatment in an aging society, Medical Anthropology Quarterly, 25(2), pp. 209–231. doi: 10.1111/j.1548-1387.2011.01150.x
- Koons, C. and Langreth, R. (2015) How marketing turned the EpiPen into a billion-dollar business—Bloomberg business, Bloomberg Business Week.
- Lakoff, A. (2008) The generic biothreat, or, how we became unprepared, Cultural Anthropology, 23(3), pp. 399–428. doi: 10.1111/j.1548-1360.2008.00013.x
- Latour, B. (1999) Pandora’s Hope: Essays on the Reality of Science Studies (Cambridge, MA: Harvard University Press).
- Latour, B. and Woolgar, S. (1986) Laboratory Life: The Construction of Scientific Facts, 2nd ed. (Princeton, NJ: Princeton University Press).
- Lock, M. (2002) Twice Dead: Organ Transplants and the Reinvention of Death (Berkeley: University of California Press).
- Mackenzie, D. (2006) An Engine, Not a Camera: How Financial Models Shape Markets (Cambridge, MA: MIT Press).
- MacKenzie, D. A. (2009) Material Markets: How Economic Agents are Constructed (Oxford: Oxford University Press).
- Marx, K. (1976) Capital Volume I, B. Fowkes, ed. (New York: Penguin Books).
- Masco, J. (2008) “Survival is your business”: Engineering ruins and affect in nuclear America, Cultural Anthropology, 23(2), pp. 361–398. doi: 10.1111/j.1548-1360.2008.00012.x
- Massumi, B. (2010) The future birth of the affective fact: the political ontology of threat, in: M. Gregg and G. J. Seigworth (Eds) The Affect Theory Reader, pp. 52–70 (Durham, NC: Duke University Press).
- Maurer, B. (2002) Repressed futures: financial derivatives’ theological unconscious, Economy and Society, 31(1), pp. 15–36. doi: 10.1080/03085140120109231
- Morgenson, G. (2016) EpiPen price rises could mean more riches for Mylan executives, The New York Times. Available at https://www.nytimes.com/2016/09/04/business/at-mylan-lets-pretend-is-more-than-a-game.html (accessed 24 April 2017).
- Muniesa, F. (2012) A flank movement in the understanding of valuation, The Sociological Review, 59(s2), pp. 24–38.
- Mylan N. V. (2016) Form 10-Q, June 30, 2016, Washington, DC: Mylan N. V.
- Panofsky, A. (2011) Generating sociability to drive science: patient advocacy organizations and genetics research, Social Studies of Science, 41(1), pp. 31–57. doi: 10.1177/0306312710385852
- Parker-Pope, T. (2016) How parents harnessed the power of social media to challenge EpiPen prices, The New York Times. Available at http://well.blogs.nytimes.com/2016/08/25/how-parents-harnessed-the-power-of-social-media-to-challenge-epipen-prices/ (accessed 25 August 2016).
- Parker-Pope, T. and Peachman, R. R. (2016) EpiPen price rise sparks concern for allergy sufferers, The New York Times. Available at http://well.blogs.nytimes.com/2016/08/22/epipen-price-rise-sparks-concern-for-allergy-sufferers/ (accessed 27 August 2016).
- Petryna, A. (2009) When Experiments Travel: Clinical Trials and the Global Search for Human Subjects (Princeton: Princeton University Press).
- Pollack, A. (2015) Drug goes from $13.50 a tablet to $750, overnight, The New York Times. Available at http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html (accessed 24 April 2017).
- Popken, B. (2016) Mylan CEO’s pay rose over 600 Percent as EpiPen price rose 400 percent, NBCnews.com. Available at http://www.nbcnews.com/business/consumer/mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591 (accessed 9 September 2016).
- Ramsey, L. (2016a) The price of an EpiPen has skyrocketed more than 500% since 2009—and senators are asking for answers, Business Insider. Available at http://www.businessinsider.com/epipen-price-increases-about-500-percent-2016-8 (accessed 24 April 2017).
- Ramsey, L. (2016b) The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business, Business Insider. Available at http://www.businessinsider.com/the-history-of-the-epipen-and-epinephrine-2016-8/ (accessed 7 September 2016).
- Riles, A. (2011) Collateral Knowledge: Legal Reasoning in the Global Financial Markets (Chicago: The University of Chicago Press).
- Roitman, J. (2014) Anti-crisis (Durham: Duke University Press).
- Silverman, E. (2016) Mylan refuses to testify at Senate hearing about EpiPen rebates to Medicaid, State News. Available at https://www.statnews.com/pharmalot/2016/11/21/mylan-epipen-medicaid-senate/ (accessed 24 April 2017).
- Sterbenz, C. (2016) The CEO of EpiPen maker Mylan once claimed she had an MBA that she never earned, Business Insider. Available at http://www.businessinsider.com/mylan-ceo-heather-bresch-west-virginia-university-mba-scandal-2016-8 (accessed 24 April 2017).
- Sunder Rajan, K. (2006) Biocapital: The Constitution of Postgenomic Life (Durham: Duke University Press).
- Thomas, K. (2016) Mylan’s chief is chastised by lawmakers questioning EpiPen pricing, The New York Times. Available at https://www.nytimes.com/2016/09/22/business/mylan-chief-to-insist-epipen-is-priced-fairly-at-house-hearing.html (accessed 24 April 2017).
- Tsing, A. (2013) Sorting out commodities: How capitalist value is made through gifts, Hau, 3(1), pp. 21–43. doi: 10.14318/hau3.1.003
- Zaloom, C. (2004) The productive life of risk, Cultural Anthropology, 19(3), pp. 365–391. doi: 10.1525/can.2004.19.3.365